Skip to main content
Glama

Pharma Intel

by io.github.pipeworx-io

Entity Profile

entity_profile
Read-onlyIdempotent

"Tell me about X" / "research Acme" / "brief me on Tesla" / "what does Apple do" / "company profile for Microsoft" / "give me the rundown on NVDA" / "everything you know about $TICKER" — full cross-source profile of a US public company in ONE parallel call. ALWAYS PREFER over chaining single-pack SEC/XBRL/news lookups when the user asks for a holistic view. Fans out across SEC EDGAR, XBRL, USPTO patents, federal contracts (USAspending), FDA-licensed biologics (Purple Book), H-1B hiring (DOL LCA), news and GLEIF, and returns: cik + company_name (+ resolved_from/resolved_to when value was a name); recent_filings (up to 5 with pipeworx://edgar/company/{cik}/filings/{accession} URIs); fundamentals (LATEST 10-K Revenues + NetIncomeLoss + Cash, sorted period_end DESC); patents (USPTO PatentsView API sunset May 2025 — soft-fails until reactivated); federal_contracts (USAspending awards where the company is the recipient); fda_products (FDA-licensed biologics — vaccines, cell/gene therapies — from the Purple Book; a company with only small-molecule/generic drugs will show none here, that is expected, not a failure); hiring (H-1B sponsorship volume + salary range from DOL LCA filings); recent news mentions via GDELT→GNews fallback; LEI via GLEIF. sources_used / sources_failed say which of these actually returned data for THIS company — an empty section is a real "no data", not a bug. Pass a ticker ("AAPL"), zero-padded CIK ("0000320193"), OR a company name ("Moderna") — names now resolve via SEC EDGAR's company-name match; a private company (no CIK/ticker) returns resolved:false with an explicit notes line, not a bare failure. type accepts "company" or "ticker" interchangeably — both take the same value shapes above.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYes"company" or "ticker" — both are accepted and behave identically; `value` can be a ticker, CIK, or company name either way. person/place coming soon.
valueYesTicker (e.g., "AAPL"), zero-padded CIK (e.g., "0000320193"), or company name (e.g., "Moderna") — names resolve via SEC EDGAR company-name match.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed3 schema fields changed
    • changedInput schema / properties / type / description
      Previous value: -"Entity type. Only \"company\" supported today; person/place coming soon."New value: +"\"company\" or \"ticker\" — both are accepted and behave identically; `value` can be a ticker, CIK, or company name either way. person/place coming soon."
    • changedInput schema / properties / type / enum
      Previous value: -[
-  "company"
-]New value: +[
+  "company",
+  "ticker"
+]
    • changedInput schema / properties / value / description
      Previous value: -"Ticker (e.g., \"AAPL\") or zero-padded CIK (e.g., \"0000320193\"). Names not supported — use resolve_entity first if you only have a name."New value: +"Ticker (e.g., \"AAPL\"), zero-padded CIK (e.g., \"0000320193\"), or company name (e.g., \"Moderna\") — names resolve via SEC EDGAR company-name match."
  2. Added

TDQS

A4.6/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Even though annotations already mark the tool as read-only, idempotent, and non-destructive, the description adds meaningful behavioral detail: parallel fan-out across sources, USPTO soft-failure, expected empty FDA sections, sources_used/sources_failed semantics, GDELT-to-GNews fallback, and resolution behavior for private companies. It does not contradict the annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is long, but it is front-loaded with usage examples and the core promise before enumerating sources and output sections. Most clauses carry behavioral or routing information needed because there is no output schema. It could be tightened, but the density is largely justified.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Given the tool's complexity—ten sources, heterogeneous output sections, and no output schema—the description explicitly accounts for each returned section, section-specific failure modes, empty-data semantics, source fallbacks, and resolution failure for private companies. An agent has enough context to invoke it correctly and interpret the result.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters4/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is already 100%, so the baseline is fair. The description still adds useful calling nuance: zero-padded CIK format, interchangeability of ticker/name/CIK, and the fact that `type` is purely a label with no behavioral difference. This goes beyond the schema without overstating new meaning.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description names a specific resource (US public company) and a specific behavior (building a full cross-source profile in one parallel call), and opens with concrete query examples. It also distinguishes itself from single-pack lookups, making its role among sibling research tools clear.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description explicitly says to ALWAYS PREFER this tool over chaining single-pack SEC/XBRL/news lookups for holistic questions and gives many natural-language trigger examples. It does not explicitly compare against every potentially competing sibling such as deep_research or compare_entities, so a small routing ambiguity remains.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Pharma Intel toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A4.1/5.0
Disambiguation5/5

Every tool has a clearly distinct purpose, even within the same domain (e.g., ask_pipeworx vs ask_pipeworx_grounded vs ask_pipeworx_beta are differentiated by groundedness/beta status; polymarket_edges vs polymarket_arbitrage vs polymarket_fill_risk each target discovery vs arbitrage vs execution risk). The descriptions are highly detailed, eliminating ambiguity about when to use each.

Naming Consistency4/5

All tool names use snake_case consistently, and most follow a verb-first pattern (ask_, compare_, discover_, search_, validate_), but a few are noun-first (entity_profile, polymarket_edges, recent_alerts). The style is readable and predictable, though not perfectly uniform in the verb_noun convention.

Tool Count2/5

With 37 tools, the server is heavily over-scoped, especially given the 'Pharma Intel' name that suggests a focused pharma domain. Many tools are general-purpose (prediction markets, memory, subscription management, feedback) unrelated to the server's apparent purpose, making it feel like a grab bag rather than a cohesive set.

Completeness4/5

The pharma-specific tools cover drug profiles, safety, pipeline scans, catalysts, indication landscapes, and sponsor diligence – a solid lifecycle coverage. The broader data/query/prediction-market tools also feel complete for their respective sub-domains. The only minor gaps are niche operations (e.g., updating a subscription), but these are not critical to the core workflows.

Resources